Trastuzumab Deruxtecan

證據等級: L5

預測適應症: 10 個

Trastuzumab Deruxtecan: From HER2-Targeted Oncology Use to Predicted Drug-Induced Osteoporosis

One-Sentence Summary

Trastuzumab deruxtecan (T-DXd) is a HER2-targeted antibody-drug conjugate (ADC) whose original approved indication is not specified in this evidence pack. The TxGNN model’s top prediction is Drug-Induced Osteoporosis (score 99.31%), but this candidate — and the four other top-10 predictions — is supported by zero clinical trials and zero publications, and the evidence pack’s own mechanistic analysis flags the prediction as a likely knowledge-graph artifact rather than a genuine therapeutic signal.

Quick Overview

Item	Content
Original Indication	Not specified in evidence pack (drug is classified as a HER2-targeted antibody-drug conjugate per mechanistic notes)
Predicted New Indication	Drug-Induced Osteoporosis (duplicate entry at rank 1 and 2 — likely deduplication artifact)
TxGNN Prediction Score	99.31%
Evidence Level	L5 (model prediction only, no supporting studies)
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Trastuzumab deruxtecan (T-DXd) is described in the evidence pack as a HER2-targeted antibody-drug conjugate (ADC), with a payload consisting of a topoisomerase I inhibitor (DXd). No original indication data was provided for this pack, so the traditional “original indication → new indication” mechanistic bridge cannot be constructed with confidence.

More importantly, the evidence pack’s own rationale for every one of the top 10 predictions explicitly concludes that there is no known mechanistic pathway linking a HER2/topoisomerase-I-targeted ADC to any of the predicted conditions (drug-induced osteoporosis, diabetic retinopathy and its severe subtype, bronchitis, or diabetic cataract). The assessment suggests these high TxGNN scores more likely reflect semantic co-occurrence in the knowledge graph (e.g., shared nodes with bone metastasis, chemotherapy-related tissue damage, or general antibody/oncology clusters) rather than a real treatment hypothesis.

Notably, for several candidates the evidence pack raises a directionally inverted concern: T-DXd carries a known class of eye toxicity (corneal/keratopathy signals) and a well-established interstitial lung disease (ILD)/pneumonitis risk. If the knowledge graph associates the drug with eye- or respiratory-related disease nodes (diabetic retinopathy, diabetic cataract, bronchitis), this may reflect the drug’s known adverse-effect profile being misread as a therapeutic signal, rather than genuine repurposing potential. This is a critical caveat for clinical interpretation.

Clinical Trial Evidence

Currently no related clinical trials registered.

(Confirmed by direct queries against ClinicalTrials.gov and ICTRP for all five unique predicted indications — drug-induced osteoporosis, severe nonproliferative diabetic retinopathy, diabetic retinopathy, bronchitis, and diabetic cataract — each returning 0 results.)

Literature Evidence

Currently no related literature available.

(Confirmed by direct PubMed queries for all five unique predicted indications, each returning 0 results.)

Denmark Market Information

No marketing authorisations are currently registered for this product in Denmark (0 licenses on file; market status: Not marketed).

Cytotoxicity

Trastuzumab deruxtecan is an antineoplastic antibody-drug conjugate (HER2-targeted delivery of a cytotoxic topoisomerase I inhibitor payload), so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy — antibody-drug conjugate (ADC) delivering a conventional cytotoxic payload (topoisomerase I inhibitor)
Myelosuppression Risk	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions
Emetogenicity Classification	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions
Monitoring Items	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions
Handling Protection	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. No drug interaction records were found in the queried database.

Note: Product label warnings and contraindications are flagged as a Blocking data gap in this evidence pack (unavailable from the regulatory source), meaning a formal safety pre-assessment cannot yet be completed for this candidate.

Conclusion and Next Steps

Decision: Hold

Rationale:

All five unique predicted indications are TxGNN model output only (Evidence Level L5), with zero corroborating clinical trials or literature.
The evidence pack’s own mechanistic review concludes there is no plausible biological rationale for any top-ranked prediction, and warns that some associations may reflect the drug’s known toxicity profile (ILD, keratopathy) rather than therapeutic potential.
Product label safety data (warnings/contraindications) is a Blocking gap, preventing a formal safety pre-assessment.
The prediction list contains duplicate entries (ranks 1–2, 3–4, 5–6, 7–8, 9–10 are identical pairs), indicating an upstream data-quality issue.

To proceed, the following is needed:

TFDA/SmPC label data (warnings, contraindications) — currently Blocking
Confirmed mechanism of action (MOA) and original approved indication(s) for this drug
Deduplication of the predicted_indications dataset at the source
If any candidate is pursued further, preclinical/mechanistic studies are required before advancing beyond S0, given the complete absence of clinical or literature evidence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.